Who is sponsoring NCT04866030?

NCT04866030 is sponsored by Shire.

What condition does NCT04866030 study?

NCT04866030 studies Attention Deficit Hyperactivity Disorder (ADHD).

Is NCT04866030 still recruiting?

NCT04866030 is currently completed. Last updated 4 October 2021.

Last reviewed 2021-10-04 · How we verify

NCT04866030

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Drug Use Study With Intuniv® in Australia

Completed Last updated 4 October 2021

What this trial tests

trial in Attention Deficit Hyperactivity Disorder (ADHD) in 100 participants. Completed in 27 August 2021.

Timeline

11 March 2019

Primary endpoint
27 August 2021

27 August 2021

Quick facts

Lead sponsor	Shire
Status	Completed
Study type	OBSERVATIONAL
Enrollment	100
Start date	11 March 2019
Primary completion	27 August 2021
Estimated completion	27 August 2021
Sites	1 location across Australia

Conditions studied

Attention Deficit Hyperactivity Disorder (ADHD) — all drugs for Attention Deficit Hyperactivity Disorder (ADHD) →

Sponsor

Shire — full company profile →

Who can join

Adults 6 to 17, any sex, with Attention Deficit Hyperactivity Disorder (ADHD). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will evaluate and analyze prescribing behaviors of physicians and determine whether Intuniv was correctly prescribed in Australia.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Attention Deficit Hyperactivity Disorder (ADHD)

Currently open trials in the same condition.

NCT06853665 — The TEAM Study - Treatment Efficacy for Autism/Attention Using Mixed Amphetamine · Phase 4 · recruiting
NCT07189442 — L-theanine and Paraxanthine for Cognitive Improvement in Adults With ADHD and ASD · NA · recruiting
NCT06960980 — Improving ADHD Teen Driving - Virtual Reality · NA · recruiting
NCT06810180 — Examination of the Dynamic Relationships of Sleep, Physical Activity, and Circadian Rhythmicity With Neurobehavioral Het · NA · recruiting
NCT06885060 — Exploring Eye Vergence Markers ADHD) and ASD · active not recruiting

Other Shire trials

Trials by the same sponsor.

NCT05067868 — A Study of Replagal in Children and Adults With Fabry Disease in India · Phase 4 · recruiting
NCT03878953 — A Clinical Study of rhPTH(1-84) Treatment in Japanese Participants With Chronic Hypoparathyroidism · Phase 3 · withdrawn
NCT04840667 — A Study of Replagal in Treatment-naïve Adults With Fabry Disease · Phase 3 · terminated
NCT04429984 — Post Marketing Surveillance (PMS) Study for Velaglucerase Alfa (VPRIV) in India · completed
NCT04440488 — ARALAST NP Alpha-1 Lung Density Chronic Obstructive Pulmonary Disease-Emphysema (COPD-E) Study · Phase 4 · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04866030 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shire
Last refreshed: 4 October 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04866030.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing